Please refer to ClinicalTrials.gov : NCT03716570.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224171

Enrollment

Registered

2018-12-05

Start date

2019-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

investigational material(s) Generic name etc : INN of investigational material : - Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigational material : c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Please refer to ClinicalTrials.gov : NCT03716570.

Exclusion criteria

Exclusion criteria: Please refer to ClinicalTrials.gov : NCT03716570.

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
safety pharmacokinetics	—

Countries

none

Contacts

Public ContactBiogen Japan Medical Information

Biogen Japan Ltd.

japan-medinfo@biogen.com+81-120-560-086

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026